DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy
Primary mitochondrial diseases (PMDs) affect approximately 1 in 4300 individuals and cause early-onset neuromuscular and multisystem dysfunction with reduced lifespan. They result from pathogenic variants in mitochondrial or nuclear DNA that impair oxidative phosphorylation. Cytochrome c oxidase (COX; complex IV) deficiency is a well-established cause of PMD, leading to a broad spectrum of phenotypes. COXFA4 (cytochrome c oxidase subunit FA4), formerly NDUFA4, is a nuclear-encoded COX subunit, but its role in disease remains poorly defined. We report the largest genetically confirmed cohort of COXFA4-related PMD to date, comprising 13 individuals from 12 families with biallelic pathogenic COXFA4 variants. All present with Leigh-like encephalopathy and complete loss of COXFA4 protein; however, patient-derived fibroblasts retain residual COX activity, with upregulation of COXFA4L2 (cytochrome c oxidase subunit FA4-like 2), a poorly characterised paralog. Here, we show that COXFA4 is a late-stage COX assembly subunit and identify a paralog-mediated compensatory mechanism with translational potential, R.D.S.P. and M.F. are supported by a Medical Research Council (UK) Transition Support award
(MR/X02363X/1). M.F., M.G.H., and R.D.S.P. receive support from a Medical Research Council
(UK) award (MC_PC_21046) to establish a National Mouse Genetics Network Mitochondria
Cluster (MitoCluster). R.D.S.P., R.W.T., and M.G.H. are supported by a Medical Research
Council (UK) strategic award (MR/S005021/1) to establish an International Centre for Genomic
Medicine in Neuromuscular Diseases (ICGNMD) and the LifeArc Centre to Treat Mitochondrial
Diseases (G125217). LifeArc is a charity registered in England and Wales under no. 1015243 and
in Scotland under no. SC037861. The opinions and interpretations presented are those of the
authors and not LifeArc’s. M.F, W.L.M., C.P., R.W.T, and R.D.S.P. are funded by the Lily
Foundation. C.P. and R.D.S.P. are funded by Muscular Dystrophy UK (MDUK). R.D.S.P. is
funded by a seedcorn award from the Rosetrees Trust and Stoneygate Foundation. A.L.F. and C.L.P. are supported by EU funding within the MUR PNRR National Center for Gene Therapy
and Drugs based on RNA Technology (Project no. CN_00000041). R.W.T receives additional
funding from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Pathological
Society, the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to
the Newcastle upon Tyne Foundation Hospitals NHS Trust and the UK NHS Highly Specialised
Service for Rare Mitochondrial Disorders of Adults and Children. C.U. is supported by Instituto
de Salud Carlos III (PI20/00057) and Ministerio de Ciencia, Innovacion y Universidades, Spain
(PID2023-147288NB-I00) and by the Caixa Research Health program (HR24-00604). JWT is
supported by Fund 42 of the Royal Free Charity., Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Tipos celulares - líneas celulares primarias